Featured Article

The Implementation and First‐Round Results of a Community‐Based Colorectal Cancer Screening Program in Shanghai, China
Yangming Gong, Peng Peng, Pingping Bao, Weijian Zhong, Yan Shi, Kai Gu, Ying Zheng, Chunxiao Wu, Sanjun Cai, Ye Xu, Jun Sheng and Fan Wu
The Oncologist 2018; first published on March 14, 2018; doi: 10.1634/theoncologist.2017-0451


Recent Translated Articles from The Oncologist


Volume 23: Number 4, April 2018


Breast Cancer

早期和局部晚期化生性乳腺癌:监测、流行病学和最终结果 (SEER) 2010-2014 中根据受体状态的表现和生存率
Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014
Mary C. Schroeder, Priya Rastogi, Charles E. Geyer Jr., Lance D. Miller, Alexandra Thomas
The Oncologist 2018; 23:481-488; first published on January 12, 2018; doi:10.1634/theoncologist.2017-0398


Academia-Pharma Intersect: Breast Cancer

生物仿制药非格司亭的安全性特征(Zarzio/Zarxio):III期研究的综合分析
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies
Nadia Harbeck, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, Kimberly Blackwell
The Oncologist 2018; 23:403-409; first published on January 9, 2018; doi:10.1634/theoncologist.2017-0348


Clinical Trial Results

氯法拉滨治疗复发性或难治性低度恶性或中度恶性B细胞或T细胞淋巴瘤患者的I期剂量递增研究
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Francine Marie Foss, Terri Parker
The Oncologist 2018; 23:397-e30; first published on February 7, 2018; doi:10.1634/theoncologist.2017-0658

Peutz-Jeghers 综合征患者的化学预防:经验总结
Chemoprevention in Patients with Peutz‐Jeghers Syndrome: Lessons Learned
Justin de Brabander, Ferry A.L.M. Eskens, Susanne E. Korsse, Evelien Dekker, Pieter Dewint, Monique E. van Leerdam, Susanne van Eeden, Heinz‐Josef Klümpen
The Oncologist 2018; 23:399-e33; first published on January 25, 2018; doi:10.1634/theoncologist.2017-0682

在晚期实体瘤患者中进行的Pilaralisib(一种泛I类PI3K抑制剂)片剂剂型I期研究
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Gerald Edelman, Jordi Rodon, Joanne Lager, Christelle Castell, Jason Jiang, Eliezer M. Van Allen, Nikhil Wagle, Neal I. Lindeman, Lynette M. Sholl, Geoffrey I. Shapiro
The Oncologist 2018; 23:401-e38; first published on March 28, 2018; doi:10.1634/theoncologist.2017-0691